PALI · Palisade Bio, Inc.
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-07-09 | Baltera Robert Jr. |
Director |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.9298 to $1.98. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
Common Stock
|
25,000 |
| 2026-07-08 | Baltera Robert Jr. |
Director |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.98 to $2.00. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
Common Stock
|
20,000 |
| 2026-07-07 | Baltera Robert Jr. |
Director |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $2.00 to $2.07. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
Common Stock
|
30,000 |
| 2026-07-07 | Finley John David |
Director, CEO, CFO |
Convert↓
Filing footnotes — Series 2 Common Stock Purchase Warrant (Direct)
As adjusted in accordance with the terms of the Series 2 Common Stock Purchase Warrants following the public offering that closed on October 2, 2025. Reflects adjustments pursuant to the Issuer's 1-for-50 reverse stock split effective November 15, 2022, and the Issuer's 1-for-15 reverse stock split effective April 5, 2024. Represents Series 2 Common Stock Purchase Warrants received as part of the Units purchased by Reporting Person. The Series 2 Warrants became exercisable upon receipt of stockholder approval per Nasdaq rules, which was obtained on October 6, 2022. |
Series 2 Common Stock Purchase Warrant
|
133 |
| 2026-07-07 | Finley John David |
Director, CEO, CFO |
Convert↑
|
Common Stock
|
133 |
| 2026-07-07 | Finley John David |
Director, CEO, CFO |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale reported in this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.045 to $2.09, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. |
Common Stock
|
146,798 |
| 2026-07-07 | Jones Mitchell Lawrence |
Chief Medical Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale reported in this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.045 to $2.06, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. |
Common Stock
|
51,880 |
| 2026-07-06 | Finley John David |
Director, CEO, CFO |
Convert↑
Filing footnotes — Common Stock (Direct)
The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs") granted on February 9, 2026. Includes 1,899 shares acquired under the Issuer's Employee Stock Purchase Plan on May 20, 2026. In addition, the amount of securities beneficially owned was reduced by 66 shares due to an administrative error in the total reported in the Form 4 filed February 13, 2026. |
Common Stock
|
335,167 |
| 2026-07-06 | Baltera Robert Jr. |
Director |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $2.04 to $2.068. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
Common Stock
|
20,000 |
| 2026-07-06 | Jones Mitchell Lawrence |
Chief Medical Officer |
Convert↓
Filing footnotes — Restricted Stock Units (Direct)
Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest with respect to 1/6th of the shares on July 6, 2026 and quarterly thereafter over the following 10 quarters, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. |
Restricted Stock Units
|
131,167 |
| 2026-07-06 | Finley John David |
Director, CEO, CFO |
Convert↓
Filing footnotes — Restricted Stock Units (Direct)
Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest with respect to 1/6th of the shares on July 6, 2026 and quarterly thereafter over the following 10 quarters, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. |
Restricted Stock Units
|
335,167 |
| 2026-07-06 | Jones Mitchell Lawrence |
Chief Medical Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs") granted on February 9, 2026. Includes 1,459 shares acquired under the Issuer's Employee Stock Purchase Plan on May 20, 2026. |
Common Stock
|
131,167 |
| 2026-07-02 | Baltera Robert Jr. |
Director |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.97 to $1.99. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
Common Stock
|
10,000 |
| 2026-07-01 | Baltera Robert Jr. |
Director |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.97 to $1.99. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
Common Stock
|
20,000 |
| 2026-06-10 | Chuang Emil |
Director |
Convert↓
Filing footnotes — Restricted Stock Units (Direct)
The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, with the first installment vesting on the earlier of (i) the date of the 2026 annual meeting of stockholders or (ii) the anniversary of October 6, 2025, subject to the Reporting Person's continuous service with the Issuer through such date. |
Restricted Stock Units
|
20,200 |
| 2026-06-10 | Williams Donald Allen |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, with the first installment vesting on the earlier of (i) the date of the 2027 annual meeting of stockholders or (ii) the anniversary of June 10, 2026, subject to the Reporting Person's continuous service with the Issuer through such date. |
Common Stock
|
1,498,900 |
| 2026-06-10 | Zwick Jordan Michael |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2026-06-10 | Zwick Jordan Michael |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, with the first installment vesting on the anniversary of June 10, 2026, subject to the Reporting Person's continuous service with the Issuer through such date. |
Common Stock
|
336,904 |
| 2026-06-10 | Williams Donald Allen |
Director |
Convert↓
Filing footnotes — Restricted Stock Units (Direct)
The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, with the first installment vesting on the earlier of (i) the date of the 2026 annual meeting of stockholders or (ii) the anniversary of October 6, 2025, subject to the Reporting Person's continuous service with the Issuer through such date. |
Restricted Stock Units
|
60,666 |
| 2026-06-10 | Wei Binxian |
Director |
Convert↓
Filing footnotes — Restricted Stock Units (Direct)
The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, with the first installment vesting on the earlier of (i) the date of the 2026 annual meeting of stockholders or (ii) the anniversary of October 6, 2025, subject to the Reporting Person's continuous service with the Issuer through such date. |
Restricted Stock Units
|
20,200 |
| 2026-06-10 | Wei Binxian |
Director |
Convert↑
Filing footnotes — Common Stock (Direct)
The Reporting Person was granted RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs vested on June 10, 2026. |
Common Stock
|
20,200 |
| 2026-06-10 | Baltera Robert Jr. |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, with the first installment vesting on the anniversary of June 10, 2026, subject to the Reporting Person's continuous service with the Issuer through such date. |
Common Stock
|
336,904 |
| 2026-06-10 | Chuang Emil |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, with the first installment vesting on the earlier of (i) the date of the 2027 annual meeting of stockholders or (ii) the anniversary of June 10, 2026, subject to the Reporting Person's continuous service with the Issuer through such date. |
Common Stock
|
592,300 |
| 2026-06-10 | Wei Binxian |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, with the first installment vesting on the earlier of (i) the date of the 2027 annual meeting of stockholders or (ii) the anniversary of June 10, 2026, subject to the Reporting Person's continuous service with the Issuer through such date. |
Common Stock
|
592,300 |
| 2026-06-10 | Baltera Robert Jr. |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2026-06-10 | Williams Donald Allen |
Director |
Convert↑
Filing footnotes — Common Stock (Direct)
The Reporting Person was granted RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs vested on June 10, 2026. |
Common Stock
|
60,666 |
| 2026-06-10 | Chuang Emil |
Director |
Convert↑
Filing footnotes — Common Stock (Direct)
The Reporting Person was granted RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs vested on June 10, 2026. |
Common Stock
|
20,200 |
| 2026-02-12 | Jones Mitchell Lawrence |
Chief Medical Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale reported in this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. |
Common Stock
|
1,989 |
| 2026-02-12 | Finley John David |
Director, CEO, CFO |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale reported in this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. |
Common Stock
|
3,896 |
| 2026-02-11 | Finley John David |
Director, CEO, CFO |
Convert↑
Filing footnotes — Common Stock (Direct)
The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs") granted on February 11, 2025. Includes 4,444 shares acquired under the Issuer's Employee Stock Purchase Plan on November 20, 2025. |
Common Stock
|
13,333 |
| 2026-02-11 | Jones Mitchell Lawrence |
Chief Medical Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs") granted on February 11, 2025. Includes 3,400 shares acquired under the Issuer's Employee Stock Purchase Plan on November 20, 2025. |
Common Stock
|
8,000 |
| 2026-02-11 | Jones Mitchell Lawrence |
Chief Medical Officer |
Convert↓
Filing footnotes — Restricted Stock Units (Direct)
Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three equal annual installments beginning on February 11, 2026, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. |
Restricted Stock Units
|
8,000 |
| 2026-02-11 | Finley John David |
Director, CEO, CFO |
Convert↓
Filing footnotes — Restricted Stock Units (Direct)
Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three equal annual installments beginning on February 11, 2026, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. |
Restricted Stock Units
|
13,333 |
| 2026-02-09 | Jones Mitchell Lawrence |
Chief Medical Officer |
Award↑
Filing footnotes — Restricted Stock Units (Direct)
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock, provided that, until such time as the Issuer has sufficient shares of Issuer common stock reserved under its 2021 Equity Incentive Plan to issue upon settlement of all outstanding grants thereunder, the RSUs may be settled upon vesting in cash. The RSUs shall vest with respect to 1/6th of the shares on July 6, 2026 and quarterly thereafter over the following 10 quarters, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. |
Restricted Stock Units
|
787,000 |
| 2026-02-09 | Finley John David |
Director, CEO, CFO |
Award↑
Filing footnotes — Restricted Stock Units (Direct)
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock, provided that, until such time as the Issuer has sufficient shares of Issuer common stock reserved under its 2021 Equity Incentive Plan to issue upon settlement of all outstanding grants thereunder, the RSUs may be settled upon vesting in cash. The RSUs shall vest with respect to 1/6th of the shares on July 6, 2026 and quarterly thereafter over the following 10 quarters, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. |
Restricted Stock Units
|
2,011,000 |
| 2026-01-16 | Williams Donald Allen |
Director |
Buy↑
|
Common Stock
|
5,000 |
| 2026-01-09 | Williams Donald Allen |
Director |
Buy↑
|
Common Stock
|
5,000 |
| 2025-10-06 | Wei Binxian |
Director |
Award↑
Filing footnotes — Restricted Stock Units (Direct)
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock, provided that, until such time as the Issuer has sufficient shares of Issuer common stock reserved under its 2021 Equity Incentive Plan (the "Plan") to issue upon settlement of all outstanding grants thereunder, the RSUs may be settled upon vesting in cash. This amended Form 4 is being filed to correct the previously reported grant amount of 510,700 RSUs to the Reporting Person. The Issuer has rescinded the grant of 450,100 RSUs of the previously reported grant of 510,700 RSUs. The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, with the first installment vesting on the earlier of (i) the date of the 2026 annual meeting of stockholders or (ii) the anniversary of October 6, 2025, subject to the Reporting Person's continuous service with the Issuer through such date. |
Restricted Stock Units
|
60,600 |
| 2025-10-06 | Chuang Emil |
Director |
Award↑
Filing footnotes — Restricted Stock Units (Direct)
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock, provided that, until such time as the Issuer has sufficient shares of Issuer common stock reserved under its 2021 Equity Incentive Plan (the "Plan") to issue upon settlement of all outstanding grants thereunder, the RSUs may be settled upon vesting in cash. This amended Form 4 is being filed to correct the previously reported grant amount of 510,700 RSUs to the Reporting Person. The Issuer has rescinded the grant of 450,100 RSUs of the previously reported grant of 510,700 RSUs. The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, with the first installment vesting on the earlier of (i) the date of the 2026 annual meeting of stockholders or (ii) the anniversary of October 6, 2025, subject to the Reporting Person's continuous service with the Issuer through such date. |
Restricted Stock Units
|
60,600 |
| 2025-10-06 | Jones Mitchell Lawrence |
Chief Medical Officer |
Award↑
Filing footnotes — Restricted Stock Units (Direct)
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock, provided that, until such time as the Issuer has sufficient shares of Issuer common stock reserved under its 2021 Equity Incentive Plan to issue upon settlement of all outstanding grants thereunder, the RSUs may be settled upon vesting in cash. The RSUs shall vest with respect to 1/3rd of the shares on October 6, 2026 and quarterly thereafter over the following eight quarters, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. |
Restricted Stock Units
|
7,665,800 |
| 2025-10-06 | Finley John David |
Director, CEO, CFO |
Award↑
Filing footnotes — Restricted Stock Units (Direct)
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock, provided that, until such time as the Issuer has sufficient shares of Issuer common stock reserved under its 2021 Equity Incentive Plan to issue upon settlement of all outstanding grants thereunder, the RSUs may be settled upon vesting in cash. The RSUs shall vest with respect to 1/3rd of the shares on October 6, 2026 and quarterly thereafter over the following eight quarters, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. |
Restricted Stock Units
|
9,179,400 |
| 2025-10-06 | Williams Donald Allen |
Director |
Award↑
Filing footnotes — Restricted Stock Units (Direct)
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock, provided that, until such time as the Issuer has sufficient shares of Issuer common stock reserved under its 2021 Equity Incentive Plan (the "Plan") to issue upon settlement of all outstanding grants thereunder, the RSUs may be settled upon vesting in cash. This amended Form 4 is being filed to correct the previously reported grant amount of 1,538,700 RSUs to the Reporting Person. The Issuer has rescinded the grant of 1,356,700 RSUs of the previously reported grant of 1,538,700 RSUs. The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, with the first installment vesting on the earlier of (i) the date of the 2026 annual meeting of stockholders or (ii) the anniversary of October 6, 2025, subject to the Reporting Person's continuous service with the Issuer through such date. |
Restricted Stock Units
|
182,000 |
| 2025-09-04 | Jones Mitchell Lawrence |
Chief Medical Officer |
Award↑
Filing footnotes — Phantom Units (Direct)
Each Phantom Unit is the economic equivalent of one share of the Issuer's common stock. The Phantom Units vest in 12 equal quarterly installments beginning on November 5, 2025, subject to the Reporting Person's continuous service through each applicable vesting date. Vested Phantom Units shall be settled solely in cash based on the fair market value of an equal number of shares of the Issuer's common stock on the earliest to occur of any of the following events: (a) termination of the Reporting Person's continuous service by the Issuer without Cause; (b) a Liquidity Change in Control of the Issuer; or (c) 7th anniversary of the grant date, in each case as such capitalized terms are defined in the Issuer's Phantom Unit Plan. |
Phantom Units
|
289,000 |
| 2025-09-04 | Finley John David |
Director, CEO, CFO |
Award↑
Filing footnotes — Phantom Units (Direct)
Each Phantom Unit is the economic equivalent of one share of the Issuer's common stock. The Phantom Units vest in 12 equal quarterly installments beginning on November 5, 2025, subject to the Reporting Person's continuous service through each applicable vesting date. Vested Phantom Units shall be settled solely in cash based on the fair market value of an equal number of shares of the Issuer's common stock on the earliest to occur of any of the following events: (a) termination of the Reporting Person's continuous service by the Issuer without Cause; (b) a Liquidity Change in Control of the Issuer; or (c) 7th anniversary of the grant date, in each case as such capitalized terms are defined in the Issuer's Phantom Unit Plan. |
Phantom Units
|
323,400 |
| 2025-09-04 | Wei Binxian |
Director |
Award↑
Filing footnotes — Phantom Units (Direct)
Each Phantom Unit is the economic equivalent of one share of the Issuer's common stock. The Phantom Units vest in three equal annual installments beginning on August 5, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Vested Phantom Units shall be settled solely in cash based on the fair market value of an equal number of shares of the Issuer's common stock on the earliest to occur of any of the following events: (a) termination of the Reporting Person's continuous service with the Issuer; (b) a Liquidity Change in Control (as defined in the Phantom Unit Plan) of the Issuer; or (c) 7th anniversary of the grant date. |
Phantom Units
|
18,800 |
| 2025-09-04 | Chuang Emil |
Director |
Award↑
Filing footnotes — Phantom Units (Direct)
Each Phantom Unit is the economic equivalent of one share of the Issuer's common stock. The Phantom Units vest in three equal annual installments beginning on August 5, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Vested Phantom Units shall be settled solely in cash based on the fair market value of an equal number of shares of the Issuer's common stock on the earliest to occur of any of the following events: (a) termination of the Reporting Person's continuous service with the Issuer; (b) a Liquidity Change in Control (as defined in the Phantom Unit Plan) of the Issuer; or (c) 7th anniversary of the grant date. |
Phantom Units
|
18,800 |
| 2025-09-04 | Williams Donald Allen |
Director |
Award↑
Filing footnotes — Phantom Units (Direct)
Each Phantom Unit is the economic equivalent of one share of the Issuer's common stock. The Phantom Units vest in three equal annual installments beginning on August 5, 2026, subject to the Reporting Person's continuous service through each applicable vesting date Vested Phantom Units shall be settled solely in cash based on the fair market value of an equal number of shares of the Issuer's common stock on the earliest to occur of any of the following events: (a) termination of the Reporting Person's continuous service with the Issuer; (b) a Liquidity Change in Control (as defined in the Phantom Unit Plan) of the Issuer; or (c) 7th anniversary of the grant date. |
Phantom Units
|
64,400 |
| 2025-07-18 | Chuang Emil |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option shall vest with respect to 8.33% of the underlying shares subject to the option in equal quarterly installments such that the option shall be fully vested on the three-year anniversary of July 18, 2025, subject to the reporting person's continued service as a member of the Issuer's Board of Directors through each applicable vesting date. |
Stock Option (Right to Buy)
|
8,000 |
| 2025-07-07 | Chuang Emil |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2025-02-11 | Jones Mitchell Lawrence |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to this option shall vest and become exercisable in twelve equal quarterly installments over a three-year period with vesting commencing on May 11, 2025, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. |
Stock Option (Right to Buy)
|
29,000 |